Clinical Roundup American Heart Association tool measures heart disease risk in testicular cancer survivors February 27, 2026Vol.52 No.08
Clinical Roundup “Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds February 27, 2026Vol.52 No.08
Clinical Roundup Renal and cardiovascular risks persist decades after testicular cancer treatment February 27, 2026Vol.52 No.08
Clinical Roundup Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer February 27, 2026Vol.52 No.08
Clinical Roundup Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds February 27, 2026Vol.52 No.08
Clinical Roundup Follicular lymphoma may be curable with chemoimmunotherapy combo, data from 15-year trial suggests February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC February 27, 2026Vol.52 No.08
A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risksRespirators (restricted by federal regulation) may or may not be the answer February 20, 2026Vol.52 No.07By Sara Willa Ernst
News Analysis NIH Director Bhattacharya named acting CDC director in latest public health shakeupThe temporary appointment concentrates vast authority in the hands of one person February 20, 2026Vol.52 No.07By Claire Marie Porter
